Bubendorf, Switzerland, Friday, October 21, 2016 – CIS Pharma’s novel solubilization strategy for hydrophobic drugs has successfully reached the proof of concept phase. The Cellophil® Smart Polymer technology platform creates water-soluble formulations for a number of model drugs such as cyclosporine A. The technology can be applied to a large number of water-insoluble drugs, improving the bioavailability and tolerance for drugs used in different indications such as ophthalmology. The platform is customizable to specific drugs, site of delivery and pharmaceutical activity.

About Cellophil

Cellophil® is a platform of polymers that are based on natural amino acids linked to acrylics. The platform polymers show excellent biocompatibility, superior to the polymers most commonly used in the implant and drug-delivery industry. The safety of Cellophil® polymers has been demonstrated: no cytotoxic, allergic or hemolytic potential was observed. And it was also shown that the specific structures of Cellophil® Smart Polymers offer a good environment for cellular attachment. The patented Cellophil Smart Polymers comprise unique structures providing ideal contact points for the attachment and the delivery of therapeutics. Cellophil® is loaded with active compounds, from small molecules up to large protein-based drugs. The release kinetic of the immobilized therapeutics is varied using different linker chemistry.

About CIS Pharma AG

CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. CIS Pharma is located in the life science cluster of Basel, Switzerland. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of currently used medical treatments. For more information about the company, visit our website www.cis-pharma.com. — Discovery is our business, progress our passion.